Arvee Laboratories (India) Limited has informed the Exchange regarding Outcome of Board Meeting held on May 09, 2025.
ARVEE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Arvee Laboratories' board approved FY25 audited results showing revenue from operations of ₹3,848.72 lakhs, up about 27% from ₹3,034.52 lakhs in FY24, while profit after tax more than doubled to ₹214.74 lakhs (FY24: ₹105.18 lakhs), lifting EPS to ₹1.95 from ₹0.95. However, Q4 performance was muted — revenue was nearly flat at ₹645 lakhs and Q4 PAT actually fell to ₹6.92 lakhs from ₹11.60 lakhs a year earlier. The statutory auditors (Nirav Patel & Associates) issued an unmodified opinion on the results. A worrying point is that operating cash flow swung sharply negative to ₹(3.73) lakhs versus ₹670.79 lakhs in FY24, and cash and bank balances dropped to ₹21.10 lakhs from ₹185.01 lakhs. The board also re-appointed internal auditors and appointed M/s. Jalan Alkesh & Associates as secretarial auditor for a 5-year term starting April 1, 2025.
The strong full-year revenue and profit growth are positive for shareholders, but the steep fall in operating cash flow and the 89% drop in cash balance raise red flags about working-capital pressure and near-term liquidity. Q4 weakness and the need to watch cash generation closely temper the otherwise encouraging earnings story.